Archive for January 2018
Brief-Biocartis & Immunexpress Partnership For A Sepsis Host Immune Response Test
Immunexpress and Biocartis enter an agreement to develop and commercialize SeptiCyte™ technology for use on sample-to-result Idylla™ platform.
Read MoreBiocartis, Immunexpress Partner to Develop Sepsis Test
Biocartis and Immunexpress partner to develop a fully automated sepsis test, allowing for fast near-patient testing, resulting in potentially life-saving clinical information.
Read MoreBiocartis, Immunexpress Partner to Develop Sepsis Test
Biocartis & Immunexpress sign partnership for a sepsis host immune response test on the Idylla™ platform.
Read MoreBiocartis Partnership May Enable Immunexpress to Move Sepsis Test to Point of Care
Biocartis Group NV (‘Biocartis’), an innovative molecular diagnostics company and Immunexpress have entered into a partnership agreement aimed at the development and commercialization of Immunexpress’ SeptiCypte™ test for use on Biocartis’ sample-to-result Idylla™ platform.
Read MoreBiocartis & Immunexpress Sign Partnership for a Sepsis Host Immune Response Test on the Idylla™ platform
Mechelen (Belgium)/Seattle (United States), 24 January 2018 – Biocartis Group NV (‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART) and Immunexpress Pty Ltd (‘Immunexpress’), a host response molecular diagnostic company, committed to improving clinical and economic outcomes for suspected sepsis patients, today announce that they have entered into a partnership agreement aimed at the…
Read More